Explore the vast range of titles available.

The aim of the study was to evaluate selected indicators of protein metabolism in cows fed with fodder contaminated with mycotoxins after application of a mycotoxin deactivator product (MDP). Experimental group (Exp.)—10 cows, fed total mixed ration (TMR) containing: 0.769 mg/kg-deoxynivalenol and 0.032 mg/kg-zearalenone TMR DM. Control group (Con.)—10 cows fed TMR without mycotoxins. In the exp. cows, the mycotoxin deactivator product (MDP) Mycofix Plus was used in the form of an additive to TMR in the amount of 10 g/head/day for 90 days. Blood was taken in Exp. group three times, before MDP administration, and on days 30 and 90 of its use. In the con. group, blood was collected once. All cows were assessed for free amino acids, total protein, albumin, globulin, and urea. Cows with mycotoxicosis (before MDP administration) showed low total protein, albumin, total-essential (TEAA) and total-non-essential amino acids (TNEAA) compared to after MDP administration (p < 0.01). Compared to the control group, TNEAA values were lower and TEAA higher on all study dates (p < 0.001). The results of our research showed the negative impact of mycotoxins on the parameters of protein metabolism in cows, and the use of MDP improved the processes of protein metabolism and improved the overall health of cows.

The aim of the study was to compare selected leukocyte subpopulations and the serum amyloid A (SAA) concentration in the peripheral blood of cows at different stages of lactation. The blood of cows receiving a probiotic as a dietary supplement was compared with the blood of cows not receiving it. The research was conducted on 20 pregnant dairy cows randomly divided into two groups of 10 cows each. The experimental group consisted of cows given the probiotic as a feed supplement. The control group consisted of cows that were fed without supplementation. Blood was drawn six times for testing: 7 days before drying; 14 days before parturition; and 7, 21, 60 and 90 days postpartum. Leukocyte immunophenotyping was performed by flow cytometry. The blood of cows administered the probiotic revealed an increased percentage of forkhead box protein 3 (Foxp3) , T CD4 and B CD25 lymphocytes and β2 CD18 and αM CD11b integrins, and persistently low SAA levels at all time points. The activity of the immune system in cows receiving the probiotic was higher than in control cows. However, the stabilisation of the immune system of the supplemented cows may be indicated by the persistence of a low level of SAA throughout the experiment. Therefore, it can be assumed that the immune system of cows treated with the probiotic more easily adapts to changes in conditions in particular lactation periods and that these cows become more resistant to infectious diseases.

The objective of this bovine peripheral blood study was a comparative assessment of the phagocytic activity of neutrophils and monocytes and of the intracellular killing capacity of neutrophils from cows given no probiotic and from cows which were administered a probiotic consisting of and . These activity types were compared during different lactation periods. A cohort of 20 pregnant dairy cows was divided into two groups of 10. The experimental group consisted of cows fed a ration supplemented with probiotics, and the control group consisted of cows fed an unsupplemented ration. Blood was drawn six times: 7 days before dry off, 14 days before parturition, and 7, 21, 60 and 90 days postpartum (DPP). The phagocytic activity of neutrophils and monocytes and the oxidative burst activity of neutrophils were determined by flow cytometry in the peripheral blood of all examined cows. Phagocytosis testing revealed increased percentages of phagocytic neutrophils and monocytes in the experimental group at 21, 60 and 90 DPP (P-value < 0.01). The mean fluorescence intensity (MFI) values for neutrophils and monocytes were higher on all days of the study (P-value < 0.01). In oxidative burst testing, the percentages of detected neutrophils and their MFI were increased in the experimental group on all days (P-value < 0.01). The use of probiotics supported dairy cows' immunity throughout the whole experiment. Probiotic supplementation may limit the occurrence of infectious diseases in these animals.

Mycotoxins in dairy cows can cause many non-specific symptoms often resulting from immune system overreaction. The study assessed the concentration of selected cytokines and acute phase proteins (APP) in cows with natural mycotoxicosis before and after using a mycotoxin neutraliser. The cytokines were tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and interleukin 10 (IL-10), and the APP were serum amyloid A (SAA) and haptoglobin (Hp). The research was carried out on an experimental group (Exp) of 10 herdmate Holstein-Friesian cows with mycotoxicosis. The control group (Con) was 10 healthy cows of the same breed from a different herd. Cows in the Exp group were administered the mycotoxin deactivator Mycofix for three months. Blood was drawn from Exp cows once before administering Mycofix and a second time after three months of its use. Blood was also drawn from Con cows at the same times. Serum levels of TNF-α, IL-6, IL-10, SAA and Hp were assessed using ELISA. The concentrations of all cytokines and Hp in Exp cows were higher before treatment (P < 0.001) than those in Con cows. After three months of administering Mycofix, the concentrations of TNF-α and IL-6 were significantly lower than their pre-treatment levels (P < 0.001). The concentrations of IL-6, IL-10, and Hp were still significantly higher than those in the Con group (P < 0.001). In cows with mycotoxicosis, simultaneous stimulation of antagonistic processes was noted: a pro-inflammatory process in the upregulation of TNF-α and IL-6, and an anti-inflammatory one in the upregulation of IL-10. Despite the absorbent's use and the resolution of clinical symptoms in Exp cows, high levels of IL-10 and Hp and IL-6 were maintained. Assessment of the level of cytokines and APP appears to be a useful and precise tool for the evaluation and application of the appropriate dose of the mycotoxin absorbent or the evaluation of its effectiveness.